SCHEMBL4387315

SCHEMBL4387315

COc1ccc(S(=O)(=O)N2CCC(=NOCc3cccc(C(F)(F)F)c3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
ALDH1A1 P00352 5/20 0.49
HTT P42858 2/20 0.49
MAPT P10636 1/20 0.49
TSHR P16473 2/20 0.48
MAPK1 P28482 1/20 0.48
POLB P06746 5/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C19 P33261 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
PKM P14618 3/20 0.45
PKLR P30613 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
USP2 O75604 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4391011 0.91 LMNA (0.54) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL4385647 0.91 LMNA (0.51) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL4391160 0.90 KMT2A (0.55) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL4380293 0.90 LMNA (0.51) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL4386291 0.90 LMNA (0.52) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL4385767 0.89 TP53 (0.53) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL4379552 0.89 LMNA (0.52) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL4376947 0.89 LMNA (0.51) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL4387475 0.88 LMNA (0.51) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL4385367 0.88 HTT (0.51) LMNASMN1; SMN2ALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 LMNA 3822/4885SMN1; SMN2 664/4885ALDH1A1 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.